1186647-69-7Relevant articles and documents
HETEROCYCLIC KINASE INHIBITORS
-
Page/Page column 115; 116, (2021/02/12)
Disclosed herein, are protein kinase inhibitors (I), (II), (III) or (IV), in particular Bruton tyrosine kinase (BTK) inhibitors, pharmaceutical compositions comprising them, processes for preparing them and uses of the inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function. In particular, the present invention relates to selective BTK inhibitors.
THERAPEUTIC INHIBITORY COMPOUNDS
-
Paragraph 00619, (2018/03/26)
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
TYROSINE KINASE INHIBITORS
-
Page/Page column 67, (2017/04/19)
The present disclosure provides compounds of formula (I) that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ("BTK") inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, au